Table A1. Patient characteristics and treatment information.

Pt No.	Age	Initial tumor Dimensions (AP × ML × SI cm)	Histology	Grade	ER	PR	HER2	Treatment
1	55	5.4 × 5.0 × 2.3	IDC	I	-	+	+	FEC and Taxol, Herceptin
2	53	7.4 × 7.0	IDC with mucinous features	I	+	+	-	Epi and Taxotere
3	41	5.3 × 4.4 × 4.7	IDC	II	+	+	+	Docetaxel, carboplatin, trastuzumab
4	65	10.0 × 10.0	IDC	I	-	-	-	AC & Taxotere
5	50	4.0 × 5.0	IDC	III	+	+	+	AC + docetaxel, trastuzumab
6	33	3.0 × 3.0	IDC	I	+	+	-	AC & Taxol
7	33	5.4.0 × 5.0 × 8.0	IDC	II	+	+	+	AC + docetaxel, paclitaxel, trastuzumab
8	48	4.9.0 × 4.9.0 × 4.1.0	IDC	III	+	+	-	AC + docetaxel
9	36	4.4 × 3.9 × 5.8	IDC	II	+	+	-	AC + paclitaxel
10	40	4.4 × 3.4	IDC	III	-	-	-	AC + paclitaxel
11	62	12.0 × 14.0	IDC	II-III	-	-	-	FEC + docetaxel
12	59	6 × 2.3 × 4.3	IDC	III	-	-	-	AC + paclitaxel
13	53	8.4 × 9.4 × 12.7	Metaplastic carcinoma	III	-	-	-	AC + cisplatinum, gemcitabine platinum
14	48	7 × 9.0	IDC	II	+	+	+	AC-Taxol and Herceptin
15	50	13.0 × 11.0	IDC	III	-	-	-	AC + paclitaxel
16	49	7.1 × 5.5 × 8.9	IDC	III	-	-	+	Docetaxel, trastuzumab
17	40	3 × 2.4 × 3.0	IDC	III	+	+	+	AC + paclitaxel, trastuzumab
18	56	2.4 × 2.7 × 3.2	IDC	II	-	-	+	AC + paclitaxel, trastuzumab
19	49	2.4 × 2.8 × 1.4	IDC	II	-	-	+	AC-Taxol and Herceptin
20	47	5.2 × 4.0 × 4.0	IDC	NA	+	+	-	FEC + docetaxel
21	52	4.1 × 3.0 × 2.5	IDC	NA	+	+	-	AC + docetaxel, paclitaxel
22	44	9.9 × 4.5 × 9.7	IDC	III	+	+	+	AC + paclitaxel, trastuzumab
23	38	9.0 × 6.6 × 6.0	IDC	II*	+	+	-	AC + paclitaxel
24	58	1.9 × 1.4 × 1.6	IDC with basal like features	III	-	-	-	AC + paclitaxel
25	35	5.9	IDC	III	-	-	-	AC-Taxol
26	38	8.0 × 8.0	IDC	III	-	-	+	Dose-dense AC + paclitaxel, trastuzumab
27	47	8.0 × 10.0	IDC	II	+	+	-	Dose-dense AC + paclitaxel
28	57	7.9 × 4.1 × 5.5	IDC	III	-	-	-	Dose-dense AC + paclitaxel
29	47	6.3 × 4.1 × 7.4	IDC	NA	-	-	+	Dose-dense AC + paclitaxel, trastuzumab
30	55	6.6 × 12.8 × 6.8	IDC	II	+	+	-	AC + paclitaxel
31	32	6.0 × 7.0 × 3.0	IMC	Ϯ	+	+	+	AC + paclitaxel + Herceptin
32	38	2.3 × 2.5 × 2.5 & 1.0 × 1.0 × 0.7	IDC	III	-	-	-	AC + paclitaxel
33	45	6.5 × 5.0	IDC	I	+	+	+	AC-Taxol + Herceptin
34	55	10 × 5 × 10.5	IDC	III	-	-	-	dose dense AC + taxol
35	59	8.0 × 5.7 x3.0	IDc	II	+	+	+	FEC + docetaxel, trastuzumab
36	37	2.5 × 2.0	IDC	III	+	+	-	dose dense AC + taxol
37	50	9.0 × 7.0 × 3.0	IDc	II	+	+	-	AC + paclitaxel
38	54	3.6 × 3.6 × 2.3	IDC	NA	+	-	-	TC
39	55	1.6 × 1.2	ILC @ 12H; IDC @ 2H	NA	+	+	-	FEC-D
40	50	7.3 × 2.5 × 7.3	IDC	III	-	-	-	FEC-D
41	55	3.3 × 3.4 × 3.4	IDC	III	-	-	-	TC
42	44	3.0 × 3.5 × 1.5	IDC with prominent lymphoid stroma	III	-	-	-	FEC-D
43	60	8.7 × 9.0 × 5.2	Invasive lobular carcinoma	NA	+	-	-	FEC-D
44	64	6.4 × 3.2 × 8.7	ILC(Invasive lobular carcinoma	II	+	+	-	FEC-D
45	67	3.2 × 8.7	IDC	II	-	-	-	FEC-D
46	52	2.6 × 1.2 × 1.6	IDC	II	-	-	-	FEC-D
47	47	8.0 × 7.0	IDC	III	-	-	-	FEC-D
48	56	10.0 × 10.0	IDC	II	+	+	+	Paclitaxel and Herceptin
49	45	2.3 × 2.0	IDC	NA	+	+	+	FEC-DH.
50	59	4.9 × 2.1 × 1.4	IDC	II	+	+	-	FEC-D
51	66	3.5 × 5.2 × 2.1	IDC	II-III	+	+	+	TCH
52	49	1.8 × 2.1 × 2.1	IDC	I	+	+	+	dose dense AC + taxol + Herceptin
53	39	6.3	Invasive carcinoma with ductal & lobular features	II*	+	+	-	FEC-D
54	62	4.4 × 6.3 × 3.3	IDC	III	-	-	-	dose dense AC/taxol
55	58	5.2 × 5.2 × 4.4	IDC	I	+	+	+	dose dense AC/Taxol+Herceptin
56	58	2.3 × 4.0 × 2.3;1.6 × 1.8 × 1.6	IDC	III	-	-	+	Taxotere/Carboplatin and Trastuzumab (TCH)
57	45	2.7 × 3.2 × 2.0	IDC	III	+	+	-	ACT
58	29	4.2 × 2.9 × 2.7	IDC	III	+	+	-	dose dense AC paclitaxol

ML = medial-lateral, SI = superior-inferior, and AP = anterior-posterior

^Ϯtubular formation =3/3, nuclear pleomorphism = 2/3, mitotic score could not be determined since tumor was present in small clusters

^*indicates that the information was obtained from mastectomy report and not the biopsy report, as this was the only available source of this information.